These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23297098)

  • 1. Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance.
    Khattak M; Larkin J
    World J Urol; 2014 Feb; 32(1):19-29. PubMed ID: 23297098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential use of targeted agents in the treatment of renal cell carcinoma.
    Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
    Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy in metastatic renal cell cancer.
    Ravaud A; Gross-Goupil M; Bellmunt J
    Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
    Al-Marrawi MY; Rini BI; Harshman LC; Bjarnason G; Wood L; Vaishampayan U; MacKenzie M; Knox JJ; Agarwal N; Al-Harbi H; Kollmannsberger C; Tan MH; Rha SY; Donskov FN; North S; Choueiri TK; Heng DY;
    Target Oncol; 2013 Sep; 8(3):203-209. PubMed ID: 23300029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic therapy for metastatic renal cell carcinoma].
    Kramer MW; Steffens S; von Klot C; Merseburger AS; Kuczyk MA
    Aktuelle Urol; 2012 Jul; 43(4):265-8. PubMed ID: 22869498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma.
    Ryan CW
    J Oncol Pharm Pract; 2017 Jan; 23(1):43-55. PubMed ID: 26625878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.
    Felici A; Bria E; Tortora G; Cognetti F; Milella M
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1545-57. PubMed ID: 23253221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
    Albiges L; Choueiri T; Escudier B; Galsky M; George D; Hofmann F; Lam T; Motzer R; Mulders P; Porta C; Powles T; Sternberg C; Bex A
    Eur Urol; 2015 Jan; 67(1):100-110. PubMed ID: 24841777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
    Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
    Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
    Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.
    Kroeger N; Choueiri TK; Lee JL; Bjarnason GA; Knox JJ; MacKenzie MJ; Wood L; Srinivas S; Vaishamayan UN; Rha SY; Pal SK; Yuasa T; Donskov F; Agarwal N; Tan MH; Bamias A; Kollmannsberger CK; North SA; Rini BI; Heng DY
    Eur Urol; 2014 Jun; 65(6):1086-92. PubMed ID: 23916693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.
    Ishihara H; Takagi T; Kondo T; Tachibana H; Yoshida K; Omae K; Iizuka J; Kobayashi H; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):559-567. PubMed ID: 29327159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
    J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How far is the horizon? From current targets to future drugs in advanced renal cancer.
    Kruck S; Merseburger AS; Stenzl A; Bedke J
    World J Urol; 2014 Feb; 32(1):69-77. PubMed ID: 23657355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to targeted therapy in renal-cell carcinoma.
    Rini BI; Atkins MB
    Lancet Oncol; 2009 Oct; 10(10):992-1000. PubMed ID: 19796751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase inhibitors in renal cell carcinoma.
    Daste A; Grellety T; Gross-Goupil M; Ravaud A
    Expert Opin Pharmacother; 2014 Feb; 15(3):337-51. PubMed ID: 24328606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.
    Iacovelli R; Cartenì G; Sternberg CN; Milella M; Santoni M; Di Lorenzo G; Ortega C; Sabbatini R; Ricotta R; Messina C; Lorusso V; Atzori F; De Vincenzo F; Sacco C; Boccardo F; Valduga F; Massari F; Baldazzi V; Cinieri S; Mosca A; Ruggeri EM; Berruti A; Cerbone L; Procopio G
    Eur J Cancer; 2013 Jun; 49(9):2134-42. PubMed ID: 23518211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science.
    Porta C; Sabbatini R; Procopio G; Paglino C; Galligioni E; Ortega C
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1571-7. PubMed ID: 23181412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
    Bamias A; Karavasilis V; Gavalas N; Tzannis K; Samantas E; Aravantinos G; Koutras A; Gkerzelis I; Kostouros E; Koutsoukos K; Zagouri F; Fountzilas G; Dimopoulos MA
    Int J Clin Oncol; 2019 Apr; 24(4):411-419. PubMed ID: 30374686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.